Investor Presentation

Adjusted EBITDA and GAAP Net Income/(Loss) Fourth Quarter Adj EBITDA: $12.2 M ● ● Adj. EBITDA Margin: 17.7% Excluding Maryland start up expenses, Q4 adj. EBITDA margin was 19.3%. Q4 GAAP net loss from continuing operations $2.0 million. 4 TERRASCEND Full Year Adj EBITDA: $38.8 M Adj. EBITDA Margin: 15.7% Reflects competitive conditions and flattening of Pennsylvania medical market, partially offset by New Jersey adult use launch. CSE: TER | OTCQX: TRSSF) ● ● GAAP Net loss from continuing operations for the full year 2022 was $299.4 million*. * Includes $311 million impairment of goodwill and intangibles related to Michigan reporting unit, as previously disclosed p. 21

View entire presentation